Lux Biosciences To Present at
Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference

JERSEY CITY, N.J., October 29, 2007-- Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, announced today that Ulrich Grau, President and CEO, will present a company overview at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference. The presentation will take place at 12:00 pm ET on Monday, November 5th, 2007, at the New York Palace Hotel in New York City.

The presentation will be webcast live and may be accessed at http://www.wsw.com/webcast/rrshq12/lux. An archived version of the webcast will be available at the same location for 30 days following the presentation.

About Lux Biosciences

Lux Biosciences is a privately held biotechnology company dedicated to the identification, optimization, development and commercialization of products for the treatment of ophthalmic diseases. The company's business strategy is characterized by:

• A focus on compounds already marketed or with clinical proof-of-concept in non-ophthalmic indications that Lux Biosciences will develop as unique, targeted therapies for corresponding ophthalmic diseases, with potentially greater efficacy and safety than existing treatments.

• A clinical-stage portfolio of projects including: i) LX211, a next-generation calcineurin inhibitor that has potential in several ophthalmic diseases and, as such, represents a pipeline of product opportunities; and ii) LX201, a silicone matrix ocular (episcleral) implant that steadily releases therapeutic doses of cyclosporine A locally to the eye. Both the LUMINATE pivotal clinical program for LX211 for the treatment of uveitis, as well as the LUCIDA pivotal clinical program with LX201 for the prevention of corneal transplant rejection were initiated in early 2007.

• Proprietary product-enabling bio-erodible polymer technologies that facilitate targeted and sustained delivery of molecules to the eye.
   

For more information on Lux Biosciences, please visit the company’s website at www.luxbio.com.

###

CONTACTS: 

Lux Biosciences, Inc.
Ulrich Grau, Ph.D.
+1 201 946 0221
Ulrich.grau@luxbio.com
 

Kureczka/Martin Associates (media)
Joan Kureczka
+1 415-821-2413
Jkureczka@comcast.net